精神分裂症患者抗胆碱能药物负荷与认知损害相关
该研究基于美国五所大学招募的1,120例精神分裂症或分裂情感性障碍门诊患者,采用横断面设计与探索性结构方程建模,分析抗胆碱能药物负荷与认知功能的关系。结果显示,抗胆碱能认知负荷(ACB)评分越高,Penn计算机神经认知成套测验(PCNB)各认知域表现越差,控制人口学特征、临床症状及氯丙嗪等效抗精神病药剂量后效应仍显著。
要点
- 抗胆碱能药物负荷在精神分裂症患者中普遍且显著,涉及多种药物类别。
- ACB评分越高,PCNB所有认知域表现越差,其他认知测验结果类似。
- 控制人口学特征、症状及氯丙嗪等效剂量后,抗胆碱能负荷与认知损害的关联仍显著。
核心结论
- 精神分裂症患者的抗胆碱能药物负荷显著、常见且由多种药物类别造成,并与所有认知域的损害相关。
- 来自所有药物类别(包括常规诊疗中使用的精神药物)的抗胆碱能负荷应纳入治疗决策,并在精神分裂症认知功能研究中予以考虑。
研究设计与样本
- 横断面数据分析,采用推断统计与探索性结构方程建模,评估抗胆碱能药物负荷与认知的关系。
- 研究对象为来自美国五所大学社区招募的1,120例精神分裂症或分裂情感性障碍患者,属于精神分裂症遗传学联盟-2(COGS-2)研究。
- 每位参与者的处方药物按改良抗胆碱能认知负荷(ACB)量表评分并求和,认知功能以Penn计算机神经认知成套测验(PCNB)各认知域表现评估。
主要发现
- ACB评分与认知表现显著相关,较高ACB组在PCNB所有测试认知域上的得分均低于较低ACB组。
- 在其他认知测验上也观察到类似效应。
- 控制人口学特征及疾病严重度的潜在替代指标(包括临床症状和氯丙嗪等效抗精神病药剂量)后,效应仍然显著。
临床怎么用
- 在精神分裂症门诊患者的治疗决策中,应综合考虑所有药物类别带来的抗胆碱能负荷,以优化认知结局。
- 评估精神分裂症患者认知功能的研究应纳入抗胆碱能药物负荷这一因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Many psychotropic medications used to treat schizophrenia have significant anticholinergic properties, which are linked to cognitive impairment and dementia risk in healthy subjects. Clarifying the impact of cognitive impairment attributable to anticholinergic medication burden may help optimize cognitive outcomes in schizophrenia. The aim of this study was to comprehensively characterize how this burden affects functioning across multiple cognitive domains in schizophrenia outpatients. METHODS: Cross-sectional data were analyzed using inferential statistics and exploratory structural equation modeling to determine the relationship between anticholinergic medication burden and cognition. Patients with a diagnosis of schizophrenia or schizoaffective disorder (N=1,120) were recruited from the community at five U.S. universities as part of the Consortium on the Genetics of Schizophrenia-2. For each participant, prescribed medications were rated and summed according to a modified Anticholinergic Cognitive Burden (ACB) scale. Cognitive functioning was assessed by performance on domains of the Penn Computerized Neurocognitive Battery (PCNB). RESULTS: ACB score was significantly associated with cognitive performance, with higher ACB groups scoring worse than lower ACB groups on all domains tested on the PCNB. Similar effects were seen on other cognitive tests. Effects remained significant after controlling for demographic characteristics and potential proxies of illness severity, including clinical symptoms and chlorpromazine-equivalent antipsychotic dosage. CONCLUSIONS: Anticholinergic medication burden in schizophrenia is substantial, common, conferred by multiple medication classes, and associated with cognitive impairments across all cognitive domains. Anticholinergic medication burden from all medication classes-including psychotropics used in usual care-should be considered in treatment decisions and accounted for in studies of cognitive functioning in schizophrenia.
引用
- Joshi YB, Thomas ML, Braff DL, et al. Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia. Am J Psychiatry. 2021. PMID: 33985348. doi:10.1176/appi.ajp.2020.20081212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。